[Tetravalent anti-meningococcal vaccine: serologic and clinical evaluation].
Meningococcal disease is the only bacterial meningitis able to cause an epidemic and the mortality due to this disease is all but negligible; therefore the active immunization induced by a vaccine that includes a large portion of Neisseria meningitidis serogroups responsible for the immunization of subjects at risk. Tetravalent vaccine containing polysaccharides of the serogroups A, C, Y, W135 has given good results both for tolerability and immune response. Considering the epidemic situation in Italy, this vaccine could be an excellent strategy "to behead" possible epidemics and/or hyperendemics due to a known serogroups.
Vescia
N
N
Mastroeni
I
I
Pompa
M G
MG
Signorelli
C
C
Fara
G M
GM
D000328:Adult; D000907:Antibodies, Bacterial / Q000096:biosynthesis; D000942:Antigens, Bacterial / Q000276:immunology; D001428:Bacterial Vaccines / Q000276:immunology; D004196:Disease Outbreaks / Q000517:prevention & control; D005260:Female; D006801:Humans; D007558:Italy / Q000453:epidemiology; D008297:Male; D008585:Meningitis, Meningococcal / Q000453:epidemiology / Q000517:prevention & control*; D022401:Meningococcal Vaccines; D008875:Middle Aged; D009345:Neisseria meningitidis / Q000276:immunology; D011135:Polysaccharides, Bacterial / Q000276:immunology
D000907:Antibodies, Bacterial; D000942:Antigens, Bacterial; D001428:Bacterial Vaccines; D022401:Meningococcal Vaccines; D011135:Polysaccharides, Bacterial
Vaccino antimeningococcico tetravalente: valutazione sierologica e clinica.